CURE

FDA Approves PD-L1 Test to Guide Keytruda Use in Esophageal and GEJ Cancer

U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...
The Pharma Letter

Keytruda regimen wins EU nod in PD-L1-positive platinum-resistant ovarian cancer

Merck & Co’s Keytruda (pembrolizumab)—in combination with paclitaxel, with or without bevacizumab—has been approved in the ...
The American Journal of Managed Care

Search Continues for New Biomarkers in NSCLC

Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...

Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx

Agilent Technologies (A) announced that it has received U.S. Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with ...
ascopubs.org

Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A ...

Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. Outcome of chemo-immunotherapy for extensive-stage small-cell lung cancer according ...
Healio

AI could improve accuracy of PD-L1 scoring for non-small cell lung cancer

AI may calculate PD-L1 scores for non-small cell lung cancer more accurately than manual assessment, results of an analysis ...
The Scientist

ImmuneOncia Therapeutics and Lonza Collaborate to Manufacture Danburstotug, a PD-L1 Antibody Targeting Immuno-Oncology

ImmuneOncia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on immuno-oncology, and Lonza, one of the ...